Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies.
Selenium and Prostate Cancer: Analysis of Individual Participant Data From Fifteen Prospective Studies.
复制标题
DOI：
10.1093/jnci/djw153
复制
发表时间：
2016-11
期刊：
影响因子：
--
通讯作者：
Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group
中科院分区：
文献类型：
--
作者：
Allen NE;Travis RC;Appleby PN;Albanes D;Barnett MJ;Black A;Bueno-de-Mesquita HB;Deschasaux M;Galan P;Goodman GE;Goodman PJ;Gunter MJ;Heliövaara M;Helzlsouer KJ;Henderson BE;Hercberg S;Knekt P;Kolonel LN;Lasheras C;Linseisen J;Metter EJ;Neuhouser ML;Olsen A;Pala V;Platz EA;Rissanen H;Reid ME;Schenk JM;Stampfer MJ;Stattin P;Tangen CM;Touvier M;Trichopoulou A;van den Brandt PA;Key TJ;Endogenous Hormones, Nutritional Biomarkers and Prostate Cancer Collaborative Group
背景：一些观察性研究表明，较高的硒水平与较低的前列腺癌风险相关，但通常太小，不能提供准确的相关性估计，特别是根据疾病的阶段和级别。方法：来自15项前瞻性研究的合作研究人员提供了关于血液或趾甲硒浓度与前列腺癌风险的个人参与者记录(主要来自欧洲白人血统的男性)。用多变量调整的条件Logistic回归估计硒浓度对前列腺癌的优势比。所有的统计检验都是双面的。结果：全血硒与总前列腺癌的发病风险无关(基于4527例患者和6021例对照受试者的多变量调整优势比[OR]=1.01，95%可信区间[CI]=0.83~1.23)。然而，疾病侵袭性(即晚期和/或前列腺癌死亡，P异质性=0.01)存在异质性，高血硒与侵袭性疾病的低风险相关(OR = 0.43，95%CI = 0.21~0.87)，但与非侵袭性疾病无关。指甲硒与总前列腺癌呈负相关(OR = 为0.2 9，95%CI = 为0.2 2~0.40，P趋势和0.0 0 1，基于1970年病例和2 0 86例对照)，包括非侵袭性疾病(OR = 0.33，95%CI = 0.2 2~0.5 0)和侵袭性疾病(OR = 0.18，95%CI = 0.11~0.31，P异质性=.08)。结论：指甲而不是血液中的硒浓度与总前列腺癌的风险呈负相关，可能是因为指甲是长期接触硒的更可靠的标志。血液和指甲中的硒浓度都与侵袭性疾病的风险降低有关，这一点值得进一步研究。
Background: Some observational studies suggest that a higher selenium status is associated with a lower risk of prostate cancer but have been generally too small to provide precise estimates of associations, particularly by disease stage and grade. Methods: Collaborating investigators from 15 prospective studies provided individual-participant records (from predominantly men of white European ancestry) on blood or toenail selenium concentrations and prostate cancer risk. Odds ratios of prostate cancer by selenium concentration were estimated using multivariable-adjusted conditional logistic regression. All statistical tests were two-sided. Results: Blood selenium was not associated with the risk of total prostate cancer (multivariable-adjusted odds ratio [OR] per 80 percentile increase = 1.01, 95% confidence interval [CI] = 0.83 to 1.23, based on 4527 case patients and 6021 control subjects). However, there was heterogeneity by disease aggressiveness (ie, advanced stage and/or prostate cancer death, Pheterogeneity = .01), with high blood selenium associated with a lower risk of aggressive disease (OR = 0.43, 95% CI = 0.21 to 0.87) but not with nonaggressive disease. Nail selenium was inversely associated with total prostate cancer (OR = 0.29, 95% CI = 0.22 to 0.40, Ptrend < .001, based on 1970 case patients and 2086 control subjects), including both nonaggressive (OR = 0.33, 95% CI = 0.22 to 0.50) and aggressive disease (OR = 0.18, 95% CI = 0.11 to 0.31, Pheterogeneity = .08). Conclusions: Nail, but not blood, selenium concentration is inversely associated with risk of total prostate cancer, possibly because nails are a more reliable marker of long-term selenium exposure. Both blood and nail selenium concentrations are associated with a reduced risk of aggressive disease, which warrants further investigation.